Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Peptron inc.
Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.
With the recent completion of GMP manufacturing facilities and sizable funding, South Korean peptide therapeutics company Peptron is set to begin a Phase II clinical trial of sustained release exenatide for Parkinson’s, which if successful could pave the way to a first-in-class, disease-modifying treatment for the disease.
- Controlled Release
- Drug Delivery
- Synthesis Technologies, Production Processes
Drug Discovery Tools